PRIMARY INTRAVITREAL BEVACIZUMAB FOR SUBFOVEAL CHOROIDAL NEOVASCULARIZATION IN AGE-RELATED MACULAR DEGENERATION: Results of the Pan-American Collaborative Retina Study Group at 12 Months Follow-up

@article{Arevalo2008PRIMARYIB,
  title={PRIMARY INTRAVITREAL BEVACIZUMAB FOR SUBFOVEAL CHOROIDAL NEOVASCULARIZATION IN AGE-RELATED MACULAR DEGENERATION: Results of the Pan-American Collaborative Retina Study Group at 12 Months Follow-up},
  author={J. Fernando Arevalo and Jans Fromow-Guerra and Juan Gonzalo S{\'a}nchez and Maur{\'i}cio Maia and Mar{\'i}a H Berrocal and Lihteh Wu and Mario Saravia and Rog{\'e}rio Alves Costa},
  journal={Retina},
  year={2008},
  volume={28},
  pages={1387-1394}
}
Purpose: To report the 12-month anatomic and Early Treatment Diabetic Retinopathy Study best-corrected visual acuity (BCVA) response after primary intravitreal bevacizumab (Avastin™, Genentech Inc., San Francisco, CA) (1.25 mg or 2.5 mg) in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Methods: Sixty-three eyes of 63 consecutive patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration, a mean age of… 

INTRAVITREAL BEVACIZUMAB FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION: Effect on Different Subfoveal Membranes

After an intravitreal application of bevacizumab given as therapy for exudative age-related macular degeneration at 2-month intervals, the patient's gain in visual acuity did not depend on the type of the subfoveal neovascular membranes.

VISUAL OUTCOMES AND GROWTH FACTOR CHANGES OF TWO DOSAGES OF INTRAVITREAL BEVACIZUMAB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: A Randomized, Controlled Trial

Baseline aqueous vascular endothelial growth factor level might have a role in predicting angiographic response after bevacizumab injections, and three monthly intravitreal 1.25-mg and 2.5-mg injections seemed to result in better visual outcome than 2.

RETREATMENT WITH ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY BASED ON CHANGES IN VISUAL ACUITY AFTER INITIAL STABILIZATION OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: 3-Year Follow-up Results

After stabilization of the disease, a monthly follow-up of optical coherence tomography and re-treatment based on morphologic, clinical, and vision outcomes may increase the efficacy in patients with neovascular related macular degeneration under anti–vascular endothelial growth factor treatment.

Intravitreal injection of triamcinolone combined with bevacizumab for choroidal neovascularization associated with large retinal pigment epithelial detachment in age-related macular degeneration

Combined IVB and IVTA therapy seems to be an effective and safe procedure to treat CNV associated with large PED in AMD.

Intravitreal Ranibizumab versus Thermal Laser Photocoagulation in the Treatment of Extrafoveal Classic Choroidal Neovascularization Secondary to Age-Related Macular Degeneration

Intravitreal ranibizumab showed promising results in BCVA improvement and decrease in macular thickness in patients with extrafoveal classic CNV due to AMD, with a small number of injections.

An intravenous microdose of bevacizumab for the treatment of pigment epithelial detachment associated to age-related macular degeneration refractory to intravitreal bevacizumab: a case report.

An intravenous injection of a microdose of bevacizumab appears to have resolved the PED with a sustained improvement of visual acuity.

Bevacizumab and Neovascular Age Related Macular Degeneration: Pathogenesis and Treatment

Improve in visual acuity, change in central retinal thickness (CRT), safety, pharmacodynamics, and possible resistance to intravitreal bevacizumab over a one-year period in eyes with neovascular AMD is studied.
...

References

SHOWING 1-10 OF 43 REFERENCES

VISUAL IMPROVEMENT FOLLOWING INTRAVITREAL BEVACIZUMAB (AVASTIN) IN EXUDATIVE AGE-RELATED MACULAR DEGENERATION

Intravitreal bevacizumab has the potential for improvement in vision in both naive and previously treated eyes for at least 6 months, and the benefit is more pronounced in eyes without prior pegaptanib and/or PDT.

INTRAVITREAL BEVACIZUMAB (AVASTIN) TREATMENT OF MACULAR EDEMA IN CENTRAL RETINAL VEIN OCCLUSION: A Short-Term Study

Initial treatment results of patients with macular edema secondary to CRVO did not reveal any short-term safety concerns and visual acuity improvement, defined as a halving of the visual angle, was seen in 14 of the 16 eyes.

INTRAVITREAL BEVACIZUMAB (AVASTIN) TREATMENT OF PROLIFERATIVE DIABETIC RETINOPATHY COMPLICATED BY VITREOUS HEMORRHAGE

Intravitreal bevacizumab resulted in marked regression of neovascularization and rapid resolution of vitreous hemorrhage and the favorable short-term results suggest further study is needed in a larger group of patients.

Acute retinal pigment epithelial tear following intravitreal bevacizumab (Avastin) injection for occult choroidal neovascularisation secondary to age related macular degeneration

Retinal pigment epithelium (RPE) tears are well recognised complications of pigment epithelial detachments (PED) in age related macular degeneration (AMD) and may arise spontaneously after trauma,

Twelve-month safety of intravitreal injections of bevacizumab (Avastin®): results of the Pan-American Collaborative Retina Study Group (PACORES)

Repeated intravitreal injections of either 1.25 mg or 2.5 mg of bevacizumab appears to be safe and well tolerated during the 1st year despite the limited follow-up, according to this retrospective, multicenter, open label, uncontrolled interventional case series.

ENHANCED EFFICACY ASSOCIATED WITH EARLY TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION WITH PEGAPTANIB SODIUM: An Exploratory Analysis

Early detection and treatment with pegaptanib may result in superior vision outcomes in patients with neovascular AMD, and this work has shown this to be true with VGF inhibition patients.